Holdings of Virtus Biotech Clinical Trials Etf
ETFis Series Trust I · Original filing · Compare with another fund · Report an error
- Net assets
- 37.3M $ including 37.3M $ in equities, 99.9 %
- Positions
- 124 in 8 countries
- Top ten
- 16.2 % of net assets
- Filed on
- Apr 30, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 101 | Vera Therapeutics Inc | 5,541 | 197.3K $ | 0.53 % |
| 102 | Rigel Pharmaceuticals Inc | 6,766 | 195.5K $ | 0.52 % |
| 103 | Monopar Therapeutics Inc | 3,699 | 192.9K $ | 0.52 % |
| 104 | Maze Therapeutics Inc | 7,102 | 188.8K $ | 0.51 % |
| 105 | REGENXBIO Inc | 19,900 | 178.5K $ | 0.48 % |
| 106 | Sana Biotechnology Inc | 53,698 | 176.7K $ | 0.47 % |
| 107 | Bicycle Therapeutics PLC | 37,047 | 174.9K $ | 0.47 % |
| 108 | Structure Therapeutics Inc | 4,115 | 170.6K $ | 0.46 % |
| 109 | Invivyd Inc | 118,970 | 166.6K $ | 0.45 % |
| 110 | Lexeo Therapeutics Inc | 28,249 | 160.9K $ | 0.43 % |
| 111 | Verastem Inc | 28,720 | 156.8K $ | 0.42 % |
| 112 | Fulcrum Therapeutics Inc | 21,230 | 151.4K $ | 0.41 % |
| 113 | First Tracks Biotherapeutics Inc | 6,139 | 142.9K $ | 0.38 % |
| 114 | Keros Therapeutics Inc | 12,830 | 142.7K $ | 0.38 % |
| 115 | Altimmune Inc | 52,374 | 136.2K $ | 0.36 % |
| 116 | ZENAS BIOPHARMA INC | 6,799 | 131.4K $ | 0.35 % |
| 117 | Olema Pharmaceuticals Inc | 8,351 | 120.3K $ | 0.32 % |
| 118 | WaVe Life Sciences Ltd | 16,665 | 117.7K $ | 0.32 % |
| 119 | Viridian Therapeutics Inc | 8,542 | 115.1K $ | 0.31 % |
| 120 | Compass Therapeutics Inc | 53,489 | 94.7K $ | 0.25 % |
| 121 | Upstream Bio Inc | 10,169 | 93.4K $ | 0.25 % |
| 122 | Replimune Group Inc | 27,112 | 69.7K $ | 0.19 % |
| 123 | MEREO BIOPHARMA GROUP PLC | 127,193 | 34.1K $ | 0.09 % |
| 124 | Gossamer Bio Inc | 76,668 | 28.2K $ | 0.08 % |
Sector breakdown
- Unattributed 100.0 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- United States 86.3 %
- Canada 3.7 %
- Netherlands 3.1 %
- Cayman Islands 2.4 %
- Ireland 2.0 %
- United Kingdom 1.6 %
- British Virgin Islands 0.6 %
- Singapore 0.3 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 106 | 32.2M $ | 86.34 % |
| 2 | Canada | 4 | 1.4M $ | 3.72 % |
| 3 | Netherlands | 4 | 1.2M $ | 3.08 % |
| 4 | Cayman Islands | 3 | 901.6K $ | 2.42 % |
| 5 | Ireland | 2 | 729.4K $ | 1.96 % |
| 6 | United Kingdom | 3 | 580K $ | 1.55 % |
| 7 | British Virgin Islands | 1 | 229.6K $ | 0.62 % |
| 8 | Singapore | 1 | 117.7K $ | 0.32 % |
Cite this page
Titelia. "Holdings of Virtus Biotech Clinical Trials Etf". https://titelia.com/en/funds/S000047353